Rigel rises after entering licensing deal with Spanish company to market ITP treatment
Wednesday, 23 January 2019 Rigel Pharmaceuticals Inc (NASDAQ:RIGL) climbed Wednesday after reporting that it has entered into an exclusive license and supply agreement with a Spanish company to market its treatment of chronic immune thrombocytopenia (ITP) in Europe. Under the deal with Grifols SA (NASDAQ:GRFS) to commercialize fostamatinib disodium hexahydrate, Rigel said in a statement that it will receive a $30 million upfront cash payment, with the potential for $297.5 million in payments related to regulatory and commercial milestones. Shares of Rigel climbed $0.07, or 3.5%, to $2.09 in Wednesday’s Nasdaq trading. READ: Rigel Pharmaceuticals' price target is raised to US$7 by Jefferies analyst Included in the deal would be a $20 million milestone payment for European Medicines Agency approval of fostamatinib for the treatment of chronic ITP. Fostamatinib is commercially available in the US under the brand name Tavalisse. "Grifols has a broad presence in Europe and an established position in the hematology commercial landscape, which supports our goal of bringing fostamatinib to patients in these countries," said Raul Rodriguez, president and CEO of Rigel. He added that Rigel expects a decision from the European Medicines Agency by the end of 2019, meaning that the drug could start generating European revenue in 2020. In patients with ITP, the immune system attacks and destroys the body's own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding. Grifols advanced $0.38, or 2%, to $19.46 on the Nasdaq. Contact Dennis Fitzgerald at email@example.com
Michael B. Jordan has signed a first-look deal for his production company, Outlier Society, with Warner Bros. Pictures Group, Warner Bros. chairman Toby Emmerich announced Wednesday. This deal follows the company’s joint production diversity policy instituted last September. The deal also comes on...
Papa John's is hopeful it can bring founder John Schnatter along with the recently announced Starboard Value deal. According to Business Insider, Monday the company announced a $200 million investment..
SAN JUAN -- It was billed as the revolution for television ad sales - the emerging prospect of using internet-connected platforms and audience viewing data to plan, execute and measure TV ad campaigns..